Hikma Cancels Further Shares as $250m Buyback Gathers Pace

Hikma Pharmaceuticals ( (GB:HIK) ) has provided an update.

Hikma Pharmaceuticals has continued executing its recently announced $250 million share buyback, repurchasing 310,739 ordinary shares on 3 March 2026 at a volume‑weighted average price of 1,253.36 pence through Citigroup Global Markets. The company intends to cancel these shares, bringing total purchases since 26 February to 782,739 shares at a cost of £10.1 million, and leaving 221,103,714 ordinary shares in issue and an unchanged total voting rights figure that tightens the free float and may enhance earnings per share for remaining investors.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2000.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Neutral.

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. It develops, manufactures and markets injectable, branded and generic medicines, with a strong presence in the U.K. and Middle Eastern markets and a focus on hospital and specialty therapies.

Average Trading Volume: 1,032,067

Technical Sentiment Signal: Sell

Current Market Cap: £2.75B

For an in-depth examination of HIK stock, go to TipRanks’ Overview page.